Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 17;13(12):3035.
doi: 10.3390/cancers13123035.

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives

Alessandra Dall'Acqua  1 , Michele Bartoletti  2   3 , Nastaran Masoudi-Khoram  1 , Roberto Sorio  2 , Fabio Puglisi  2   3 , Barbara Belletti  1 , Gustavo Baldassarre  1
Affiliations
Review

Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives

Alessandra Dall'Acqua et al. Cancers (Basel). .

Abstract

Alterations in components of the cell-cycle machinery are present in essentially all tumor types. In particular, molecular alterations resulting in dysregulation of the G1 to S phase transition have been observed in almost all human tumors, including ovarian cancer. These alterations have been identified as potential therapeutic targets in several cancer types, thereby stimulating the development of small molecule inhibitors of the cyclin dependent kinases. Among these, CDK4 and CDK6 inhibitors confirmed in clinical trials that CDKs might indeed represent valid therapeutic targets in, at least some, types of cancer. CDK4 and CDK6 inhibitors are now used in clinic for the treatment of patients with estrogen receptor positive metastatic breast cancer and their clinical use is being tested in many other cancer types, alone or in combination with other agents. Here, we review the role of CDK4 and CDK6 complexes in ovarian cancer and propose the possible use of their inhibitors in the treatment of ovarian cancer patients with different types and stages of disease.

Keywords: CDK4/6 inhibitors; DNA damage response; cell cycle progression; combination therapy; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest related to this work.

Figures

Figure 1
Figure 1
Possible therapeutic approaches based on the use of CDK4/6i in ovarian cancer patients.
See this image and copyright information in PMC

References

    1. Hanahan D., Weinberg R.A. The Hallmarks of Cancer. Cell. 2000;100:57–70. doi: 10.1016/S0092-8674(00)81683-9. - DOI - PubMed
    1. Hanahan D., Weinberg R.A. Hallmarks of Cancer: The next Generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Nurse P. A Long Twentieth Century of the Cell Cycle and Beyond. Cell. 2000;100:71–78. doi: 10.1016/S0092-8674(00)81684-0. - DOI - PubMed
    1. Grimmler M., Wang Y., Mund T., Cilensek Z., Keidel E.-M., Waddell M.B., Jäkel H., Kullmann M., Kriwacki R.W., Hengst L. Cdk-Inhibitory Activity and Stability of P27Kip1 Are Directly Regulated by Oncogenic Tyrosine Kinases. Cell. 2007;128:269–280. doi: 10.1016/j.cell.2006.11.047. - DOI - PubMed
    1. Chu I., Sun J., Arnaout A., Kahn H., Hanna W., Narod S., Sun P., Tan C.-K., Hengst L., Slingerland J. P27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2. Cell. 2007;128:281–294. doi: 10.1016/j.cell.2006.11.049. - DOI - PMC - PubMed

LinkOut - more resources